Zealand Pharma to Participate in 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Zealand Pharma will participate in the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022. CEO Adam Steensberg and CFO Matthew Dallas will present at 9:30 a.m. EST. A live webcast will be available on Zealand’s website, with a replay archived post-presentation. Zealand is focused on peptide-based medicines, having advanced over 10 drug candidates into clinical development, including two on the market and three in late-stage development. With collaborations with Boehringer Ingelheim and AstraZeneca, Zealand aims to enhance patient access to its innovative therapies.

Positive

• Participation in a reputable healthcare conference can increase investor visibility.
• Advancement of over 10 drug candidates into clinical stages highlights strong R&D capabilities.
• Collaborations with major firms like Boehringer Ingelheim and AstraZeneca could expand market reach.

Negative

• None.

Company announcement – No. 11 / 2022

Zealand Pharma to Participate in 21^st Annual Needham Virtual Healthcare Conference

Copenhagen, DK and Boston, MA, U.S. April 4, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Chief Executive Officer Adam Steensberg and Chief Financial Officer Matthew Dallas are scheduled to participate in the 21^st Annual Needham Virtual Healthcare Conference:

21^st Annual Needham Virtual Healthcare Conference
Date: Monday, April 11, 2022
Presentation: 9:30 a.m. EST / 2:30 p.m. GMT / 3:30 p.m. CET

A live webcast of the event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

For further information, please contact:

Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com

Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com

FAQ

When is Zealand Pharma presenting at the Needham Virtual Healthcare Conference?

Zealand Pharma is scheduled to present on April 11, 2022, at 9:30 a.m. EST.

What is Zealand Pharma's focus in the biotechnology sector?

Zealand Pharma focuses on the discovery and development of peptide-based medicines.

How many drug candidates has Zealand Pharma advanced into clinical development?

Zealand Pharma has advanced more than 10 drug candidates into clinical development.

Who will represent Zealand Pharma at the conference?

CEO Adam Steensberg and CFO Matthew Dallas will represent Zealand Pharma at the conference.